Honest Company Inc vs Oruka Therapeutics Inc. Common Stock — how do they compare? Honest Company Inc trades at $5.05 (market cap $557.34M), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B). The key difference: Oruka Therapeutics Inc. Common Stock is far larger — about 9.3× Honest Company Inc's market cap, and Honest Company Inc is trading nearer its 52-week high, Oruka Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Honest Company Inc for 39 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| HNST | ORKA | |
|---|---|---|
Market Cap | $557.34M | $5.18B |
Volume | 749,013 | 490,798 |
Sector | Consumer Staples | Health |
52-Week High | $5.95 | $113.08 |
52-Week Low | $2.10 | $26.19 |
Typical Hold Time | 39 Days | 0 Days |
Enterprise Value | $460.95M | $4.31B |
Signals from Pluang's Aura AI — not financial advice
HNST trades at $5.07, down 1.74% today, with mixed technical signals showing a neutral overall trend. The company reported Q2 2026 earnings beat with $0.04 EPS versus $0.00926 expected, though revenue declined year-over-year to $371.32M in 2025. Recent news highlights institutional buying from BlackRock and Deutsche Bank, while Seeking Alpha notes the company's turnaround progress through strategic exits and cost reductions.
The stock faces headwinds from negative profitability metrics (-3.56% net margin, -6.87% ROE) and elevated P/E of 48.83, but analyst consensus targets $5.30 with 30% buy ratings. Key risks include continued margin pressure and competitive threats in personal care, while potential upside hinges on sustained operational improvements and market share gains.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →